Therefore, a useful tumor model of ERα+ breast cancer resistant to anti-hormone therapies at skeletal sites, should consider the interactions between the bone microenvironment, the immune system and ERα+ mammary tumor cells. The gene discussed is ESR1; the disease is breast carcinoma.